Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 54 15 71
Papillomatosis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 44 D010212
NCIt 50 C3713 C7440
SNOMED-CT 67 711329002 82049002
UMLS 71 C0030354 C0205875

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to squamous cell papilloma and inverted papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Cidofovir and Polihexanide have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and growth/size/body region

Wikipedia : 74 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1056)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 33.3 TP53 KRT14 CDKN2A
2 inverted papilloma 33.1 TP53 KRT13 CDKN2A
3 urinary bladder inverted papilloma 32.5 RB1 CDKN2A
4 skin papilloma 32.3 TP53 PTEN KRT14 KRT10 CDKN1A
5 anogenital venereal wart 32.2 UBE3A TP53 RB1 CDKN2A
6 oral cancer 32.2 TP53 KRT13 CDKN2A CDKN1A
7 penile cancer 32.1 TP53 RB1 PTEN CDKN2A
8 human papillomavirus infectious disease 32.0 TP53 KRT13 FLG CDKN2A CDKN1A
9 li-fraumeni syndrome 31.8 TP53 RB1 PTEN IGF2 ERBB2 CDKN2A
10 cervix uteri carcinoma in situ 31.8 TP53 RB1 CDKN2A
11 keratosis, seborrheic 31.7 TP53 KRT10 IVL CDKN2A
12 suppressor of tumorigenicity 3 31.7 UBE3A TP53 RB1 CDKN2A CDKN1A
13 cervical intraepithelial neoplasia 31.6 KRT8 IVL CDKN2A
14 cervical cancer 31.5 UBE3A TP53 RB1 PTEN KRT14 ERBB2
15 squamous cell carcinoma 31.3 TP53 RB1 PTEN IVL GSTP1 ERBB2
16 in situ carcinoma 31.3 TP53 PTEN KRT8 KRT14 ERBB2 CDKN2A
17 oropharynx cancer 31.2 UBE3A TP53 PTEN KRT14 ERBB2 CDKN2A
18 transitional cell carcinoma 31.2 TP53 PTEN KRT8 GSTP1 ERBB2 CDKN2A
19 anus cancer 31.2 UBE3A TP53 CDKN2A
20 adenocarcinoma 31.1 TP53 RB1 PTEN ERBB2 CDKN2A CDKN1A
21 leukoplakia 31.1 KRT8 KRT13 FLG
22 verrucous carcinoma 31.0 TP53 PTEN KRT10 CDKN2A
23 epidermodysplasia verruciformis 1 30.9 UBE3A TP53 KRT14
24 ductal carcinoma in situ 30.9 TP53 PTEN KRT8 KRT14 ERBB2 CDKN2A
25 vulvar intraepithelial neoplasia 30.8 TP53 CDKN2A
26 esophagitis 30.8 TP53 IL4 FLG
27 bladder urothelial carcinoma 30.8 TP53 PTEN ERBB2 CDKN2A
28 actinic keratosis 30.8 TP53 FLG CDKN2A
29 meningioma, familial 30.7 TP53 PTEN IGF2 CDKN2A AMOT
30 squamous cell carcinoma, head and neck 30.7 TP53 RB1 PTEN GSTP1 ERBB2 CDKN2A
31 keratosis 30.7 TP53 KRT14 KRT10 IVL FLG CDKN2A
32 vaginal cancer 30.7 UBE3A TP53 CDKN2A
33 small cell carcinoma 30.7 TP53 PTEN KRT8 ERBB2 CDKN2A
34 bowenoid papulosis 30.6 FLG CDKN2A
35 basaloid squamous cell carcinoma 30.6 TP53 KRT8 KRT14 KRT13 CDKN2A
36 cervical adenocarcinoma 30.6 TP53 PTEN ERBB2 CDKN2A CDKN1A
37 ameloblastoma 30.5 TP53 KRT8 KRT14
38 breast fibroadenoma 30.5 TP53 KRT8 KRT14 ERBB2
39 rhabdomyosarcoma 30.5 TP53 RB1 PTEN IGF2 ERBB2 CDKN2A
40 esophageal cancer 30.5 TYMS TP53 RB1 PTEN IGF2 GSTP1
41 glandular cystitis 30.5 TP53 KRT13
42 bladder cancer 30.5 TYMS TP53 RB1 PTEN KRT8 GSTP1
43 bowen's disease 30.5 KRT10 IVL
44 malignant astrocytoma 30.5 TP53 PTEN ERBB2 CDKN2A
45 adenosquamous carcinoma 30.5 TP53 PTEN KRT8 IVL
46 cystic teratoma 30.4 TP53 PTEN KRT10 CDKN2A
47 carcinosarcoma 30.4 TP53 PTEN ERBB2 CDKN2A
48 molluscum contagiosum 30.4 RB1 IVL FLG
49 mucoepidermoid carcinoma 30.4 TP53 KRT14 KRT13 ERBB2 CDKN2A
50 endometrial cancer 30.4 TP53 RB1 PTEN IGF2 GSTP1 ERBB2

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.28 AMOT CDKN2A ERBB2 GSTP1 IFNAR1 IGF2

MGI Mouse Phenotypes related to Papilloma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.35 AMOT CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1
2 cellular MP:0005384 10.31 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
3 cardiovascular system MP:0005385 10.29 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
4 digestive/alimentary MP:0005381 10.26 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
5 mortality/aging MP:0010768 10.25 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
6 endocrine/exocrine gland MP:0005379 10.24 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
7 integument MP:0010771 10.23 CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1 IGF2
8 embryo MP:0005380 10.21 AMOT CDKN1A CDKN2A ERBB2 IGF2 KRT8
9 liver/biliary system MP:0005370 10.09 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT8
10 reproductive system MP:0005389 10.03 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
11 neoplasm MP:0002006 10.02 CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1 KRT14
12 no phenotypic analysis MP:0003012 9.92 CDKN1A CDKN2A IFNAR1 IGF2 IL4 RB1
13 respiratory system MP:0005388 9.85 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
14 skeleton MP:0005390 9.65 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
15 vision/eye MP:0005391 9.28 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14

Drugs & Therapeutics for Papilloma

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4 113852-37-2 60613
2
Polihexanide Approved, Investigational Phase 4 28757-47-3
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
4 Disinfectants Phase 4
5 Chlorhexidine gluconate Phase 4
6 Anti-Infective Agents, Local Phase 4
7 Hypoglycemic Agents Phase 4
8 Biguanides Phase 4
9 Immunoglobulins Phase 4
10 Vaccines Phase 4
11 Antibodies Phase 4
12
Azithromycin Approved Phase 3 83905-01-5 55185 447043
13
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
14 Antibiotics, Antitubercular Phase 3
15 Anti-Bacterial Agents Phase 3
16 Penicillin G Procaine Phase 3
17 Penicillin G Benzathine Phase 3
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
20
Mycophenolic acid Approved Phase 2 24280-93-1 446541
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
23
Masoprocol Approved, Investigational Phase 1, Phase 2 27686-84-6, 500-38-9 71398
24
Lenograstim Approved, Investigational Phase 2 135968-09-1
25
nivolumab Approved Phase 2 946414-94-4
26
Hydroxyurea Approved Phase 2 127-07-1 3657
27
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
28
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
29
Nelfinavir Approved Phase 2 159989-64-7 64143
30
Pembrolizumab Approved Phase 2 1374853-91-4
31
Lenvatinib Approved, Investigational Phase 2 417716-92-8
32
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
33
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
34
Fluorouracil Approved Phase 2 51-21-8 3385
35
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
38
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
40
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
41
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
42
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
43
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
44
Epicatechin Investigational Phase 2 490-46-0 72276
45
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
46 retinol Phase 2
47 Retinol palmitate Phase 2
48 Olive Phase 2
49 Protective Agents Phase 1, Phase 2
50
Erlotinib Hydrochloride Phase 2 183319-69-9 176871

Interventional clinical trials:

(show top 50) (show all 225)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
3 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
4 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Recruiting NCT04274153 Phase 4
5 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
6 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
7 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
8 Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Recruiting NCT04459221 Phase 4 Gardasil 9, 9-Valent Intramuscular Suspension
9 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
10 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Not yet recruiting NCT04311528 Phase 4
11 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
12 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
13 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
14 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
15 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
16 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
17 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
18 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
19 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
20 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
21 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
22 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
23 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
24 An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients Completed NCT03525210 Phase 3
25 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
26 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
27 A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls Active, not recruiting NCT02834637 Phase 3 bivalent HPV vaccine;nonavalent HPV vaccine
28 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
29 Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Withdrawn NCT01058317 Phase 2, Phase 3 Propranolol
30 Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02555800 Phase 2 Bevacizumab;Cidofovir
31 Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx Unknown status NCT00002454 Phase 2
32 Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load Unknown status NCT01654822 Phase 2 topical application cervical spray;topical spray on the cervix
33 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Unknown status NCT03302858 Phase 2
34 Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial Completed NCT00454181 Phase 2 Interferon-alpha
35 A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
36 A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis Completed NCT00038714 Phase 2 SGN-00101
37 A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis Completed NCT00571701 Phase 2 celebrex (celecoxib);placebo
38 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
39 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
40 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
41 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
42 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
43 A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options Completed NCT02128126 Phase 1, Phase 2 ISA101/ISA101b
44 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
45 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus Completed NCT00154089 Phase 1, Phase 2 EM-1421
47 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
48 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
49 Ensayo clínico, Aleatorizado, Abierto, de Grupos Paralelos y Con Grupo Control, Para Explorar la Eficacia Del Gel PAPILOCARE en la reparación de la Mucosa cérvico-vaginal Con Lesiones Causadas Por VPH (Ensayo Clínico PALOMA) Completed NCT04002154 Phase 2
50 Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts Completed NCT01757392 Phase 2

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


podophyllin
PODOPHYLLIN PWDR

Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

40
Breast, Skin, Cervix, Tongue, Kidney, T Cells, Trachea

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 17352)
# Title Authors PMID Year
1
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 61 54
20395210 2010
2
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 54 61
19621447 2009
3
Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. 54 61
18681909 2009
4
Colonic adenoma with squamous metaplasia. 61 54
18701516 2009
5
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. 61 54
19411857 2009
6
FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. 54 61
19287463 2009
7
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. 54 61
19060248 2009
8
Primary adenosquamous carcinoma of the colon: report of five cases. 61 54
19562453 2009
9
Identification of human papillomavirus in esophageal squamous papillomas. 61 54
19084918 2008
10
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 61 54
18958930 2008
11
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. 61 54
18300235 2008
12
Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9. 54 61
17920185 2008
13
Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. 61 54
19516893 2008
14
On the mechanism of phenotypic conversion of human cervical adenocarcinoma HeLa cells surviving infection by influenza B virus: potential implications for biological management of adenocarcinomas. 61 54
18291599 2008
15
[Efficacy of local use of recombinant interferon alpha-2 preparations in combined treatment of recurrent respiratory papillomatosis]. 61 54
18833124 2008
16
Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. 61 54
18180113 2008
17
Overexpression of p27kip1 in urinary bladder urothelial carcinoma. 61 54
18036045 2007
18
Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. 61 54
17855174 2007
19
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. 54 61
17977825 2007
20
Carotenoids suppress proliferating cell nuclear antigen and cyclin D1 expression in oral carcinogenic models. 61 54
17369034 2007
21
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 61 54
17638654 2007
22
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. 61 54
17116360 2007
23
The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. 54 61
17367326 2007
24
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. 61 54
17551924 2007
25
A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. 61 54
17489063 2007
26
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 61 54
17847937 2007
27
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 61 54
17294450 2007
28
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 54 61
17685229 2007
29
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). 61 54
17131388 2007
30
Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 61 54
17414102 2007
31
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 54 61
17545048 2007
32
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 54 61
16698948 2007
33
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 54 61
17295644 2007
34
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 54 61
17376306 2007
35
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 54 61
17277618 2007
36
The history of the angiogenic switch concept. 61 54
16990761 2007
37
[Risk factors and clinical characteristic patients with vulvar cancer]. 61 54
17373116 2006
38
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 61 54
16965327 2006
39
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 54 61
16845792 2006
40
Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. 61 54
16624261 2006
41
Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. 54 61
16703747 2006
42
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. 54 61
16624193 2006
43
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. 54 61
16205640 2006
44
Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. 61 54
16979303 2006
45
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 61 54
17310826 2006
46
Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. 61 54
19771278 2006
47
Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. 54 61
16998598 2006
48
Markers of malignant transformation of sinonasal inverted papilloma. 61 54
16005600 2005
49
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. 54 61
16142387 2005
50
Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. 54 61
16120114 2005

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 TP53 RB1 PTEN GSTP1 ERBB2 CDKN2A
2
Show member pathways
12.65 TP53 RB1 PTEN ERBB2 CDKN2A CDKN1A
3
Show member pathways
12.64 UBE3A TP53 RB1 PTEN IL4 IGF2
4
Show member pathways
12.56 TYMS TP53 RB1 CDKN2A CDKN1A
5 12.53 TP53 PTEN ERBB2 CDKN2A CDKN1A
6
Show member pathways
12.53 TP53 RB1 PTEN IGF2 GSTP1 ERBB2
7 12.46 TYMS TP53 RB1 GSTP1 CDKN2A CDKN1A
8
Show member pathways
12.41 TP53 PTEN IL4 IGF2 CDKN1A
9
Show member pathways
12.41 KRT8 KRT14 KRT13 KRT10 IVL FLG
10
Show member pathways
12.39 TP53 RB1 PTEN CDKN2A CDKN1A
11 12.35 TP53 RB1 CDKN2A CDKN1A
12
Show member pathways
12.33 TP53 RB1 CDKN2A CDKN1A
13 12.32 TP53 RB1 PTEN CDKN2A CDKN1A
14
Show member pathways
12.29 TP53 PTEN ERBB2 CDKN1A
16 12.27 TP53 IGF2 ERBB2 CDKN1A
17 12.27 UBE3A TP53 RB1 CDKN2A CDKN1A
18
Show member pathways
12.26 TP53 RB1 IL4 IGF2 IFNAR1
19
Show member pathways
12.23 TP53 RB1 PTEN CDKN1A
20
Show member pathways
12.22 TP53 RB1 PTEN ERBB2 CDKN1A
21 12.12 TP53 RB1 PTEN CDKN2A CDKN1A
22 12.05 TP53 RB1 PTEN CDKN1A
23 12.05 TP53 RB1 PTEN IL4 IGF2 IFNAR1
24 11.89 TP53 PTEN ERBB2 CDKN2A CDKN1A
25 11.88 TP53 RB1 PTEN CDKN1A
26 11.86 UBE3A RB1 PTEN CDKN1A
27 11.84 TYMS TP53 RB1 CDKN1A
28 11.83 TP53 RB1 PTEN CDKN2A CDKN1A
29 11.79 TP53 KRT14 IL4 CDKN1A
30 11.72 TYMS RB1 CDKN1A
31 11.7 TP53 PTEN ERBB2
32 11.68 UBE3A TP53 RB1 CDKN2A CDKN1A
33 11.66 TP53 PTEN ERBB2
34 11.63 TP53 GSTP1 ERBB2 CDKN2A CDKN1A
35 11.58 TP53 RB1 ERBB2 CDKN2A CDKN1A
36 11.5 TP53 RB1 CDKN2A CDKN1A
37 11.48 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
38 11.42 TP53 RB1 PTEN CDKN1A
39
Show member pathways
11.13 TP53 CDKN2A CDKN1A
40 11.12 TP53 RB1 CDKN2A
41 10.77 TP53 CDKN1A
42
Show member pathways
10.58 TP53 CDKN1A

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.03 UBE3A UBE2L3 TYMS TP53 RB1 PTEN
2 cytosol GO:0005829 9.53 UBE3A UBE2L3 TYMS TP53 PTEN KRT8
3 cornified envelope GO:0001533 9.43 KRT10 IVL FLG
4 intermediate filament GO:0005882 9.35 KRT8 KRT14 KRT13 KRT10 FLG

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.03 TP53 PTEN IL4 GSTP1 CDKN1A
2 positive regulation of gene expression GO:0010628 10 TP53 PTEN IL4 ERBB2 CDKN2A
3 negative regulation of cell proliferation GO:0008285 9.99 TP53 RB1 PTEN CDKN2A CDKN1A
4 heart development GO:0007507 9.9 TP53 PTEN ERBB2 CDKN1A
5 protein stabilization GO:0050821 9.88 TP53 PTEN CDKN2A CDKN1A
6 regulation of cell cycle GO:0051726 9.81 TP53 RB1 PTEN CDKN1A
7 response to toxic substance GO:0009636 9.8 TYMS GSTP1 CDKN1A
8 negative regulation of protein kinase activity GO:0006469 9.8 RB1 GSTP1 CDKN2A
9 cell cycle arrest GO:0007050 9.76 TP53 RB1 CDKN2A CDKN1A
10 keratinocyte differentiation GO:0030216 9.74 KRT10 IVL FLG
11 negative regulation of cell growth GO:0030308 9.73 TP53 RB1 CDKN2A CDKN1A
12 keratinization GO:0031424 9.72 KRT8 KRT14 KRT13 KRT10 IVL
13 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.67 PTEN GSTP1 CDKN1A
14 response to arsenic-containing substance GO:0046685 9.62 PTEN CDKN1A
15 hepatocyte apoptotic process GO:0097284 9.61 RB1 KRT8
16 negative regulation of acute inflammatory response GO:0002674 9.58 IL4 GSTP1
17 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 PTEN CDKN2A CDKN1A
18 negative regulation of dendritic spine morphogenesis GO:0061002 9.56 UBE3A PTEN
19 Ras protein signal transduction GO:0007265 9.56 TP53 RB1 CDKN2A CDKN1A
20 prostate gland growth GO:0060736 9.55 UBE3A PTEN
21 signal transduction by p53 class mediator GO:0072331 9.54 TP53 CDKN1A
22 peptide cross-linking GO:0018149 9.54 KRT10 IVL FLG
23 negative regulation of immature T cell proliferation in thymus GO:0033088 9.52 ERBB2 CDKN2A
24 intestinal epithelial cell maturation GO:0060574 9.48 TYMS CDKN1A
25 replicative senescence GO:0090399 9.33 TP53 CDKN2A CDKN1A
26 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.26 RB1 PTEN CDKN2A CDKN1A
27 cornification GO:0070268 9.1 KRT8 KRT14 KRT13 KRT10 IVL FLG

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 UBE3A UBE2L3 TP53 RB1 PTEN KRT8
2 protein kinase binding GO:0019901 9.65 TP53 PTEN GSTP1 CDKN2A CDKN1A
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN1A
4 structural molecule activity GO:0005198 9.26 KRT14 KRT13 KRT10 FLG
5 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
6 disordered domain specific binding GO:0097718 8.8 TP53 RB1 CDKN2A

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....